SMRT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SMRT is not a good buy right now. The technical trend is still bearish (negative, expanding MACD) and price is slipping below nearby support (S1 ~1.635) with weak near-term pattern odds (next week expected -2.15%). Options positioning looks call-heavy, but that alone isn’t enough to outweigh deteriorating fundamentals (Q3 revenue down double-digits YoY and margins down) and only modest Street upside (PT $1.70). For an impatient buyer, the risk/reward is unfavorable at this moment—avoid/new money should stay out until price reclaims ~1.73+ and momentum stabilizes.
Trend/Momentum: Bearish. MACD histogram is negative (-0.0176) and expanding lower, signaling weakening momentum.
RSI: RSI_6 at 23.8 indicates short-term oversold conditions (prone to bounces), but oversold alone isn’t a buy signal while MACD is still worsening.
Moving Averages: Converging MAs suggest a potential base attempt, but no confirmed reversal.
Key Levels: Current $1.62 is below S1 (1.635), increasing breakdown risk toward S2 (1.574). Bullish reclaim needs a move back above the pivot (1.734), then R1 (1.834).
Pattern-based expectancy: Similar-pattern stats imply flat next day (~0.02%), weakness next week (-2.15%), and modest 1-month rebound potential (+1.85%)—not compelling for an impatient entry.
Intellectia Proprietary Trading Signals
Hedge fund activity: Buying surged (+495% over last quarter), which can support the stock if it continues.
Potential technical bounce setup: Oversold RSI can trigger short snapbacks if price reclaims 1.635–1.734 quickly.
No negative news flow this week: Absence of fresh bad headlines removes immediate event pressure (but doesn’t fix fundamentals).
puts S2 (1.
in play.
Latest quarter: 2025/Q3.
Revenue: $36.20M, down -10.63% YoY (clear top-line contraction).
Profitability: Net income -$6.27M (loss widened vs prior year by -36.81% YoY), EPS -$0.03 (down -40% YoY).
Margins: Gross margin 26.43%, down -20.44% YoY—margin compression is a key negative because it reduces operating leverage and delays a profitability path.
Overall: Growth trends are moving the wrong direction (lower revenue and margins, larger losses), which reduces the appeal of buying dips without a confirmed technical turn.
Recent change (2025-11-06): Keefe Bruyette (Ryan Tomasello) raised price target to $1.70 from $1.45 and maintained Market Perform.
Interpretation: The PT increase is mildly positive, but the unchanged neutral stance signals limited conviction. With the stock at ~$1.62, implied upside is modest, so Wall Street’s pros lean: (Pros) slightly improving outlook/valuation vs prior PT; (Cons) not enough confidence to upgrade amid weakening fundamentals.
Influential/political trading: No recent congress trading data available; insider trend is neutral (no significant activity recently).
